A second-generation B cell maturation antigen (BCMA)-targeting CAR (BCAR) was used for this study (Figure S2A); this BCAR contains 4-1BB and CD3ζ signaling domains and has shown clinical efficacy in treating human multiple myeloma (MM).59 This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.